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Abstract The crosstalk between endothelial cells and cardiomyocytes has emerged as a requisite
for normal cardiac development, but also a keypathogenic player during the onset andprogression
of cardiac disease. Endothelial cells and cardiomyocytes are in close proximity and communicate
through the secretion of paracrine signals, as well as through direct cell-to-cell contact. Here,
we provide an overview of the endothelial cell–cardiomyocyte interactions controlling heart
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development and the main processes affecting the heart in normal and pathological conditions,
including ischaemia, remodelling and metabolic dysfunction. We also discuss the possible role
of these interactions in cardiac regeneration and encourage the further improvement of in vitro
models able to reproduce the complex environment of the cardiac tissue, in order to better
define the mechanisms by which endothelial cells and cardiomyocytes interact with a final aim of
developing novel therapeutic opportunities.
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Abstract figure legend Cardiomyocytes (labelled in red by anti-α-actinin antibodies) and endothelial cells (labelled
in green by anti-CD31 antibodies) crosstalk in multiple ways, including paracrine communication (dashed arrows)
through either secreted molecules or vesicles (red circles), direct cell–cell contact (hinges) and autocrine signalling
(curved arrows). This crosstalk plays an important role during embryonic development, normal post-natal life and
several pathological conditions, thus representing a novel target for the treatment of cardiovascular disorders.
Endothelial cell–cardiomyocyte crosstalk during
development
During early embryonic development, oxygen efficiently
diffuses from the blood into the cardiac lumen to the thin
ventricularwalls. As the ventricularmass increases, oxygen
diffusion is no longer sufficient to meet the requirement
of the developing myocardium, and coronary vessels
start to emerge and infiltrate the whole heart (E10.5).
Recent evidence has identified three possible origins for
coronary endothelial cells (ECs), the proepicardium, the
endocardium and the sinus venosus, although the relative
contribution of each source still remains amatter of debate
(Red-Horse et al. 2010; Wu et al. 2012; Chen et al. 2014).
Whatever their origin, the ongoing molecular crosstalk
between ECs and cardiomyocytes (CMs) in the developing
myocardium is exciting in light of its possible relevance
for cardiac regeneration, as the ultimate goal of cardiac
regeneration is to rebuild a myocardial architecture with a
fully integrated vascular network. Indeed, ECs contribute
to the physiological and structural maturation of CMs,
as shown by studies in engineered cardiac tissue that
recapitulate heart development (described later). In this
section, wewill discuss the communications betweenCMs
and ECs during embryonic development that might also
be relevant for heart regeneration.
Cell-specific gene inactivation strategies have revealed
multiple bidirectional signals occurring in the developing
heart (Fig. 1).
On the one hand, CMs secrete a few growth factors
able to modulate the growth of blood vessels. Vascular
endothelial growth factor (VEGF)-A, herein referred
to as VEGF, is a key controller of angiogenesis. The
deletion of the gene encoding this factor, specifically in
CMs, determines reduced number of coronary micro-
vessels, thinned ventricular walls, depressed basal contra-
ctile function, induction of hypoxia-responsive genes
involved in energy metabolism and abnormal response to
β-adrenergic stimulation (Giordano et al. 2001). Despite
the fact that CMs constitute less than one-third of the
total number of cells in the heart, the CM-specific
deletion of the VEGF gene decreases total mRNA levels
by more than 85%, pointing to cardiac myocytes as
the major source of this growth factor (Giordano et al.
2001). Of note, the structure of the coronary arteries is
not affected in this condition, indicating that different
mechanisms support the development of both the cardiac
microvasculature and the major epicardial coronary
arteries. Beside stimulating angiogenesis, CM-derived
VEGF also controls endocardial-to-mesenchymal trans-
formation during the formation of cardiac cushions
(i.e. the endocardium-derived structures that build
the heart septa and valves). This requires endocardial
calcineurin/nuclear factor of activated T cells (NFAT)
signalling to repress VEGF expression in the myocardium
underlying the site of prospective valve formation (E9).
This repression of VEGF is essential for endocardial
cells to transform into mesenchymal cells (Chang et al.
2004). Soon after the onset of endocardial cushion
formation, VEGF is specifically upregulated in the atrio-
ventricular (AV) field of the heart tube, where it
negatively regulates endocardial-to-mesenchymal trans-
formation and terminates the formation of endocardial
cushions (Dor et al. 2001). CM-derived Angiopoetin-1
(Ang1) also plays a major role in cardiac vessel
development. Transgenic mice expressing Ang1 in CMs
in an inducible manner die at E12.5 because of major
cardiac malformations, including dilated atria, significant
thinning of themyocardial wall, outflow tract collapse and
absence of coronary arteries (Ward et al. 2004).
On the other hand, developing ECs send multiple
signals that contribute to myocardial development. For
instance, EC-specific deletion of the platelet-derived
growth factor (PDGF)-B gene causes major cardiac
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 00.0 Endothelial cell–cardiomyocyte crosstalk 3
abnormalities, including myocardial wall thinning,
chamber dilation, septal defects and hypertrabeculation
(Bjarnegard et al. 2004). Similar developmental defects
are observed inmice with endothelium-restricted deletion
of the tumour-suppressor gene neurofibromin (NF1),
which results in dilated endocardial cushions, septal
abnormalities and double-outlet right ventricle (Gitler
et al. 2003). Of note, these defects also occur in NF1
knock-out mice, but not in mice missing NF1 in CMs,
pointing to ECs as the most relevant source of NF1
for proper cardiac development (Gitler et al. 2003). Yet,
the pathway linking NF1 expression in ECs to proper
CM organization and cardiac tissue formation during
development is largely unknown.
Finally, perhaps the most characterized pathway of
EC–CM crosstalk during development is neuregulin
(NRG) signalling. ECs in the developing endocardium
secrete abundant levels of NRG-1, which binds the
ErbB2 and ErbB4 receptors expressed by CMs, essentially
contributing to the formation of both endocardial
Figure 1. Endothelial cell–cardiomyocyte crosstalk during
development
Secreted molecules and transcription factors mediate a bidirectional
signalling between developing endothelial cells (labelled by
anti-CD31 antibodies in green) and cardiomyocytes (labelled by
anti-α-actinin antibodies in red). The dashed arrows indicate the
direction of the signals. Nuclei are stained in blue by
4′,6-diamidino-2-phenylindole (DAPI). Ang1, angiopoietin-1; NF1,
neurofibromin-1; NRG-1, neuregulin-1; PDGF, platelet-derived
growth factor; VEGF, vascular endothelial growth factor.
cushions andmyocardial trabeculae (Meyer & Birchmeier,
1995). This essential role of NRG-1 in promoting
trabeculation is consistent with its capacity to induce
the proliferation, survival and hypertrophy of neonatal
cardiomyocytes (Zhao et al. 1998).
Endothelial cell–cardiomyocyte crosstalk during
normal post-natal life
In the adult heart, capillaries are densely distributed
throughout the myocardium, with the number of ECs
being approximately 3 times higher than that of CMs. Yet,
the large CM mass exceeds that of the smaller ECs by 25
times (Brutsaert, 2003). While ECs within the coronary
arteries functions as in any other arterial vascular system
in the body, essentially providing blood supply to the
myocardium, capillary and endocardial ECs are in close
proximity to CMs and provide multiple autocrine and
paracrine signals controlling cardiac function (Fig. 2).
In the normal adult heart, ECs release various factors
controlling CM contractility. A first player is nitric
oxide (NO), which is synthetized by the NO synthase
class of enzymes. Three isoforms of NO synthase exist,
including the neuronal (NOS1), the inducible (NOS2)
Figure 2. Endothelial cell–cardiomyocyte crosstalk during
post-natal life
Secreted molecules and gap junctions mediate a bidirectional
signalling between adult endothelial cells (labelled by anti-CD31
antibodies in green) and cardiomyocytes (labelled by anti-α-actinin
antibodies in red). Nuclei are stained in blue by DAPI. The dashed
arrows indicate the direction of the signals. Molecules secreted by
endothelial cells are indicated on the left, those secreted by
cardiomyocytes on the right, while those secreted by both cell types
are in the middle. Ang-II, angiotensin-II; ET-1, endothelin-1; FGF2,
fibroblast growth factor 2; NO, nitric oxide; NRG-1, neuregulin-1;
PGE2, prostaglandin E2; PGI2, prostacyclin; PTHrP, parathyroid
hormone-related peptide.
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and the endothelial (NOS3) isoforms. NOS1 and NOS3
are constitutively active and produce NO in response
to calcium, whereas NOS2 is inducible and increases
its production of NO upon adequate stimulation (i.e.
cytokines) and independently from calcium activation.
In the adult heart, NO is mainly produced by ECs
and, consistent with its activity on vascular smooth
muscle cells, controls the onset of ventricular relaxation
(positive lusitropy), thus optimizing pump function at
every cardiac contraction (Hsieh et al. 2006b). This effect
has been attributed to cGMP- and protein kinase G
(PKG)-mediatedphosphorylationof troponin I, leading to
myofilament calciumdesensitization, relaxationhastening
and improved distensibility (Layland et al. 2002). In
contrast, the inotropic effect exertedby lowconcentrations
of NO relies on mechanisms independent of cGMP and
possibly involving the activation of calciumandpotassium
channels through either G protein-mediated response
(Layland et al. 2002), formation of peroxynitrite (Malan
et al. 2003) or direct channel S-nitrosylation by NO (Kohr
et al. 2011). Generation of peroxynitrite is maximal in
conditions of oxidative stress, when high levels of super-
oxide anion react with NO. At the same time, ECs are
able to protect CM from oxidative stress by modulating
several buffering systems at different levels, such as
ATP-binding cassette transporter subfamily G member
2 (ABCG2) for the secretion of glutathione (Higashikuni
et al. 2012), NRG-1 (Kuramochi et al. 2004) (see also
below), tetrahydrobiopterin (BH4) (Leucker et al. 2013)
and thioredoxin (Trx) (Subramani et al. 2016). While
most of these buffering systems have been discovered in
conditions of cardiac stress (i.e. ischaemia–reperfusion
injury and pressure overload), it is plausible that they play
a major role in maintaining cardiac homeostasis.
Besides ECs, CMs also express the different endothelial
NO synthases, although at lower levels compared to ECs.
This supports a possible autocrine NO signalling in CMs,
warranting further studies using transgenic animals with
EC- and CM-specific deletion of NO signalling.
Cardiac ECs also produce abundant levels of
endothelin-1 (ET-1), a potent vasoactive peptide. In the
adult heart, ET-1 can bind either ETB receptors expressed
by ECs or ETA receptors expressed by smooth muscle cells
and CMs. The activation of ETB receptors stimulates the
release of nitric oxide and prostanoids, also preventing
apoptosis (Niwa et al. 2000). In contrast, stimulated ETA
receptors induce cell contraction by increasing intra-
cellular calcium in both smooth muscle cells and CMs
(Rich&McLaughlin, 2003). Yet, CM-specific ETA receptor
knockout mice have normal cardiac function and physio-
logically respond to either angiotensin II (Ang-II) or iso-
proterenol, indicating a minor role of this pathway in the
homeostasis of the adult heart. While the ETB receptor
is traditionally considered to be mainly expressed by ECs
and its mRNA was not detected in human CMs (Modesti
et al. 1999), recent evidence indicates that CM-specific
ETB receptor knockout mice are particularly resistant
to extreme hypoxia, consistent with previous reports
showing the presence of ETB on CM nuclear membrane
and its role controlling nuclear calcium signalling in an
intracrinemanner (Merlen et al.2013; Stobdan et al.2018).
EC Ang-II, prostacyclin (PGI2) and prostaglandin
(PG)E2 additionally contribute to cardiac contraction
control in physiological conditions, with different
responses observed dependent on dose, species
and experimental condition (in vivo versus isolated
hearts/CMs) (Brutsaert, 2003).
Beside producing small molecules and peptides, ECs
also secrete numerous proteins, including growth factors
andmatricellular proteins, able to modulate CM structure
and function (Frangogiannis, 2012). For instance, cardiac
ECs express and secrete parathyroid hormone-related
peptide (PTHrP), which exerts positive inotropic,
chronotropic and lusitropic effects in adult ventricular
CMs (Jansen et al. 2003). Over the last decades, numerous
publications have described the cardioprotective role
of a series of factors endogenously produced in the
heart, including periostin, tenascin-C, thrombospondins,
frizzled-related protein 3, insulin-like growth factor
1, connective tissue growth factor, Dickkopf-3, bone
morphogenetic protein-2 and -4, interleukin-1β and
-6, placental growth factor (PLGF), leukemia inhibitory
factor, Wnt1-induced secreted protein, midkine and
adrenomedullin, without investigating their cellular
source.Considering the abundance and locationof cardiac
ECs, it is reasonable that these cells represent an important
source of most of these cardioprotective proteins, able to
modulate cardiac contractility andCM remodelling under
stress conditions (Segers et al. 2018).
In addition to its major role during development,
NRG-1 is also essential for normal function of the adult
heart, where it continues to be expressed bymicrovascular
ECs, but not by those laying large vessels. In accordance,
both the ErbB2 and ErbB4 receptors are expressed by adult
CMs. The first evidence for a role of the NRG-1 signalling
pathway in cardiac homeostasis came from clinical studies
in patients with metastatic mammary carcinoma treated
with an anthracycline in combination with trastuzumab
(Herceptin), a monoclonal antibody against ErbB2. This
treatment is associated with a particularly high risk of
cardiotoxic cardiomyopathy and heart failure (Slamon
et al. 2001), consistent with the experimental observation
that postnatal disruption of NRG-1/ErbB signalling by
gene targeting in mice leads to dilated cardiomyopathy
(Crone et al. 2002) .
Much less is known about the signals produced by CMs
and able to regulate EC biology. Besides NO, additional
CM-secreted molecules, including ET1, fibroblast
growth factor (FGF)-2, urocortin, haem oxygenase and
adenosine, are known to control the vascular tone,
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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although the mechanism of their action and in particular
whether they mainly target ECs, smooth muscle cells or
both, remain not fully understood (Tirziu et al. 2010).
Recent data indicate that the release of pro-angiogenic
molecules by CMs in the adult heart is constitutively
inhibited by a mechanism requiring the presence of the
transcription factor RBPJ (recombination signal binding
protein for immunoglobulin κ J region) and inhibition
of hypoxia-inducible factors (HIFs), but independent
from Notch1. Deletion of rbpj in cardiomyocytes results
in VEGF up-regulation, increased capillary density
and cardioprotection from hypoxia (Diaz-Trelles et al.
2016). Thus, CMs can produce both pro-angiogenic and
angiostatic factors, the activity of which has to be finely
tuned in normal and stress conditions.
In addition to soluble factors, intercellular
communications can occur via extracellular vesicles
(Colombo et al. 2014). These vesicles shuttle a wide range
of functional lipids, proteins, mRNAs, microRNAs and
long non-coding RNAs. In particular, the relevance of
exosomal transfer in the communication between CMs
and ECs has so far been studied in vitro and in response
to pathological stimuli, such as diabetes or ischaemia, and
is therefore discussed in the next sections.
Although largely unexplored, direct cell–cell contact
might occur between ECs and CMs. Both cell types
express connexins, proteins that form gap junctions in
the plasma membrane, allowing the movement of ions,
second messengers and metabolites. The most abundant
connexins (Cx) in the heart are Cx43, Cx40 and Cx45,
which are variably expressed by CMs throughout the
different cardiac regions and are responsible for their
coupling during normal cardiac rhythm. ECs also express
various connexins, including Cx37, Cx40 and Cx43. The
first evidence for the existence of CM–EC gap junctions
was provided in 2004 by an in vitro study showing that
Cx43 junctions were associated to improved CM survival
and structural organization (Narmoneva et al. 2004).
Whilst the functional relevance of this heterocellular gap
junction has never been documented in vivo, impaired
EC–CM coupling has been proposed as one of the
mechanisms leading to arrhythmia and heart failure in
patients with hyperhomocysteinaemia. In these patients,
the elevated levels of homocysteine determine Cx43
degradation and disruption of the gap junctions, together
with peri-vascular fibrosis, both ofwhich could reasonably
contribute to the high risk for sudden cardiac death that
characterizes this condition (Givvimani et al. 2011).
Endothelial cell–cardiomyocyte crosstalk in diabetes
and metabolic dysfunction
The adult heart is composed of cells that are markedly
heterogeneous in their metabolism. CMs are the most
energy and oxygen demanding cells in the heart due
to their continuous contraction. In healthy conditions,
CMs produce most of their ATP through oxidative
phosphorylation (OxPhos), using mainly fatty acids
(70%), but also other substrates (glucose, ketones and
amino acids) as carbon sources (Kolwicz et al. 2013).
ECs instead produce 85% of their ATP anaerobically
through glycolysis, limiting fatty acid oxidation (FAO) and
OxPhos to favour thebiosynthesis of nucleotides andother
metabolites required for replication and angiogenesis
(Potente & Carmeliet, 2017).
Alterations in cardiac metabolism during metabolic
syndrome and diabetes are driving forces leading to heart
failure, as underscored by the 50–80%of deaths for cardio-
vascular diseases in patients with diabetes (http://www.
who.int/healthinfo/global_burden_disease/estimates/en/).
Although most of these cases are due to atherosclerosis,
‘diabetic cardiomyopathy’, i.e. myocardial dysfunction
in the absence of general cardiovascular risk factors, is
emerging as a significant cause of heart failure in diabetic
patients.
In type 2 diabetes, which often involves not only
hyperglycaemia but also increased levels of circulating
triglycerides, both CMs and ECs undergomassive changes
in their metabolism. In particular CMs reduce the
expression of GLUT4, resulting in decreased glucose
consumption, together with increased fatty acid uptake
and oxidation (An & Rodrigues, 2006) through the
activation of either AMP-activated protein kinase (acute
diabetes) or peroxisome proliferator-activated receptor α
(chronic diabetes) (Finck et al. 2002; Kewalramani et al.
2007). This leads to excessive production of ATP, with
consequent down-regulation of FAO-associated genes and
accumulation of lipids, leading to cardiac ‘lipotoxicity’
and diastolic dysfunction. Moreover, the low level of
glucose oxidation increases the metabolic flux toward
accessory pathways, such as the polyol and hexosamine
biosynthetic pathway, leading to accumulation of
advanced end glycation products (AGE) and increased
protein O-GlcNAcylation (Fulop et al. 2007).
On the other hand, ECs exposed to hyperglycaemia
experiencemassive oxidative stress, due to their incapacity
to metabolize the excess of glucose in the blood (Potente
& Carmeliet, 2017). In response to oxidative stress,
polyADP-ribose polymerase 1 inactivates glyceraldehyde
phosphate dehydrogenase, diverting the glucose flux from
glycolysis to accessory pathways and leading to AGE
accumulation, similar to what is observed in CMs, in
addition to increased superoxide levels (Du et al. 2003).
The increased reactive oxygen species (ROS) levels induce
eNOSuncoupling and generation of peroxynitrite, leading
to decreased NO availability and vasoconstriction (Sasaki
et al. 2008). These metabolic shifts lead to an overall
increase in oxygen consumption, vascular dysfunction and
toxic lipid accumulation sustained by oxygen shortfall and
consequent FAO inhibition.
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Clarifying the intercellular crosstalk between CMs
and ECs in modulating their respective metabolism
could suggest innovative approaches to prevent heart
failure in diabetic patients (Fig. 3). Most of the signals
from CMs to ECs modulate the ‘gatekeeper’ function
of the endothelium in controlling the uptake of fatty
acids from the bloodstream. Fatty acids circulate inside
lipoproteins and have to be hydrolysed to free fatty
acids by lipoprotein lipase (LPL), anchored to the
luminal side of the EC (Olivecrona & Olivecrona,
2010). In the heart, CMs are the major source of LPL,
which is secreted and anchored to the heparan sulfate
proteoglycans associated with the myocyte membrane.
ECs secrete heparanase to release LPLs, which are inter-
nalized through glycosylphosphatidylinositol-anchored
high density lipoprotein binding protein 1 (GPIHBP1)
and eventually translocated into the luminal side
(Camps et al. 1990). High glucose levels induce the
re-localization of endothelial heparanase from the peri-
nuclear compartment to the plasma membrane and its
secretion by coronary ECs, consistent with the increased
LPL translocation into the vessel lumenobserved inmouse
models of diabetes (Wang et al. 2009).
Figure 3. Endothelial cell–cardiomyocyte crosstalk in diabetes
and metabolic dysfunction
Secreted molecules and exosomes (red circles) mediate a
bidirectional signalling between endothelial cells (labelled by
anti-CD31 antibodies in green) and cardiomyocytes (labelled by
anti-α-actinin antibodies in red) upon exposure to high levels of
glucose (blue dots) and fatty acids (yellow dots). FA, fatty acids; LPL,
lipoprotein lipase; NO, nitric oxide; NRG-1, neuregulin-1; VEGF-B,
vascular endothelial growth factor-B.
VEGF-B is emerging as one of the key regulator
of FA uptake in the diseased heart. This factor is
abundantly expressed by adult CMs and binds the
VEGFR-1 and neuropilin-1 (NRP-1) receptors, expressed
by ECs. VEGF-B−/− mice show decreased expression
of fatty acid transporter (FATP)-3 and -4 in ECs and
reduced lipiddroplets inCMs.Consistently, the exogenous
administrationofVEGF-B enhances FAuptake in cultured
ECsbybiding toVEGFR-1 andNRP-1.When fed ahigh fat
diet or crossedwithdiabeticmouse lines,VEGF-B−/−mice
maintain an increased insulin sensitivity, with improved
blood lipid and glucose profiles (Hagberg et al. 2012).
However, the CM-specific overexpression of VEGF-B does
not alter FA uptake and lipid accumulation, but rather
leads to a metabolic shift from FAO to glucose oxidation,
as well as to an expanded coronary tree through the
activation of VEGFR-2 in cardiac ECs (Kivela et al. 2014).
Remarkably, VEGF-B expression is decreased in different
human cardiomyopathies, consistent with itsmajor role in
controlling both CM and EC metabolism in both healthy
and diseased heart (Bry et al. 2014).
In addition to secreted proteins, exosomes produced
by CMs have been shown to regulate the metabolism of
ECs, particularly in response to altered glucose levels.
Exosomes derived from glucose-starved CMs increase
the proliferation and tube formation capacity of human
umbilical vein ECs (HUVECs) and stimulate both glucose
uptake and glycolysis in cardiacmicrovascular ECs in vitro
(Garcia et al. 2016). Furthermore, CMs isolated from the
Goto–Kakizaki rat, a model of type 2 diabetes, inhibit the
angiogenicproperties of cardiacECs through the exosomal
transfer of miR-320 (Wang et al. 2014).
Do ECs regulate CM metabolism? Although very little
is known in this respect, one possible player is NRG-1,
which is normally secreted by ECs and upregulated
upon ischaemia, as mentioned earlier. This up-regulation
appears inhibited in type 1 diabetes, as diabetic rats fail
to overexpress NRG-1 and exhibit impaired membrane
localization of ErbB2 and ErbB4 receptors in CMs after
myocardial infarction. Of note, NRG-1 increases glucose
uptake in cultured CMs via ErbB2–ErbB4 heterodimers,
phosphoinositide 3-kinase α and Akt.
Another likely player in the process is NO, which
is abundantly secreted by ECs and stimulates glucose
uptake by CMs via a cGMP-dependent mechanism
(Tada et al. 2000). Whether this crosstalk is relevant in
disease conditions characterized by poor NO availability,
including diabetes and hypercholesterolaemia, is still
unknown.
Endothelial cell–cardiomyocyte crosstalk during
cardiac remodelling
Despite its highly structured architecture, the heart is an
organ capable of extensive remodelling. Immediately after
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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birth, the heart faces a pressure overload, which physio-
logically induces CM hypertrophy, resulting in the gross
enlargementof theorgan. In adult life, the samehappens to
themother’s heart duringpregnancy aswell as to thehearts
of athletes as a result of extreme and/or repetitive exercise.
Physiological hypertrophy is reversible and considered
an adaptive process aimed at decreasing the ventricular
wall stress by increasing its thickness. Morphologically,
the increase in CM area is accompanied by enhanced
angiogenesis in the absence of fibrosis. In contrast,
pathological hypertrophy is irreversible and is typically
associated with loss of myocytes, fibrotic replacement,
decreased capillary density, cardiac dysfunction, and
increased risk of heart failure and sudden death. It
usually represents the evolution of a first phase of
compensatory hypertrophy, sustained by a prolonged
wall stress and caused by various disorders, including
systemic or pulmonary hypertension, ischaemic, genetic
or metabolic cardiomyopathy.
As physiological hypertrophy normally occurs during
the first weeks after birth supporting the post-natal growth
of the heart, it is not surprising that the same molecules
mediating EC–CM crosstalk during development also
play a major role in this type of cardiac remodelling
(Fig. 4). On the one hand, CMs undergoing a first phase
Figure 4. Endothelial cell–cardiomyocyte crosstalk during
cardiac remodelling
Secreted molecules mediate a bidirectional signalling between adult
endothelial cells (labelled by anti-CD31 antibodies in green) and
cardiomyocytes (labelled by anti-α-actinin antibodies in red) during
pathological remodelling. Nuclei are stained in blue by DAPI. The
dashed arrows indicate the direction of the signals. Molecules acting
in autocrine manner are indicated by curved arrows. APLN, apelin;
ET-1, endothelin-1; IL-6, interleukin-6; NO, nitric oxide; NRG-1,
neuregulin-1; PLGF, placental growth factor; VEGF, vascular
endothelial growth factor.
of compensatory hypertrophy produce pro-angiogenic
factors (i.e. VEGF) (Zheng et al. 2001; Zentilin et al. 2010)
able to stimulate blood vessel growth to supply enough
nutrients to the growing myocardial mass. On the other
hand, enhanced coronary angiogenesis per se, as can be
achieved by cardiac-specific overexpression of angiogenic
factors, leads to cardiac hypertrophy in the absence
of any additional pro-hypertrophic stimulation (Tirziu
et al. 2007). The precise mechanism by which increased
angiogenesis induces CM hypertrophy still needs to be
fully elucidated, but it reasonably involves the secretion of
EC-derived pro-hypertrophic factors.
In pathological conditions, ECs control and promote
cardiac remodelling by the production of secreted factors
with both paracrine and autocrine effects. To limit the
degree of complexity, here we keep the focus on signals
secreted by cardiac ECs exerting a direct effect on CMs
(Fig. 4).
Besides its role in controlling cardiac homeostasis, as
discussed above, NO blunts the hypertrophic response of
cultured CMs exposed to potent pro-hypertrophic agents,
such as noradrenaline and Ang-II. Accordingly, NOS3−/−
mice spontaneously develop cardiac hypertrophy and
exhibit exaggerated hypertrophy after both myocardial
infarction and chronic pressure overload compared to
wild-type mice (Scherrer-Crosbie et al. 2001).
As mentioned before, NO stimulates the production
of cGMP by activating soluble guanylyl cyclase. Increased
levels of cGMP activate PKG, which is a negative regulator
of the pro-hypertrophic transcriptional regulator NFAT
(Fiedler et al. 2002). This axis is emerging as a key
player in the development of HF with preserved ejection
fraction (HFpEF), a syndromic condition characterized
by the impairment of proper left ventricular filling during
diastole due to increased wall stiffness. In the context of
HFpEF, various comorbidities, especially obesity, elicit a
systemic pro-inflammatory state, which is sensed by ECs
that respond by producing ROS, which in turn limit NO
availability, as mentioned before. Limited NO availability
results in low cGMP levels and impaired PKG activity,
leading to hypo-phosphorylation of titin (Fiedler et al.
2002) and subsequent increase in CM stiffness.
Release of inflammatory cytokines, including tumour
necrosis factor-α, interleukin (IL)-1, IL-6 and IL-11,
represent an interesting example of multicellular crosstalk
during pathological cardiac remodelling. These molecules
can be produced by immune cells but also by other cell
types including ECs. Besides the aforementioned effect of
inflammatorymediators onNO availability, some of these
cytokines play a more prominent role during pathological
cardiac remodelling. For instance, IL-6 is emerging as
a pro-hypertrophic and pro-fibrotic cytokine, as IL-6
knockout mice undergo attenuated cardiac remodelling
in response to both pressure overload (Zhao et al. 2016)
and administration of Ang-II, a potent mediator of CM
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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hypertrophy (Gonzalez et al. 2015). While the relevant
cellular source of IL-6 exerting these effects is still
undefined, interesting insights into the molecular
mechanisms involved have been shed by studying the
Noonan syndrome, which is determined by mutations
in the Ras–extracellular signal-regulated kinase (ERK)
pathway. Patients in which the disease is caused
by kinase-activating RAF1 alleles typically develop
pathological left ventricular hypertrophy, which is
well reproduced in knock-in mice harbouring the
Raf1(L613V/+) mutation. Interestingly, the EC-specific
expression of the mutant protein is sufficient to drive
cardiac hypertrophy and the secretion of IL-6 by
Raf1(L613V/+)-expressing ECs is essential in promoting
CM hypertrophy, clearly pointing to this interleukin as
a key mediator of the EC–CM crosstalk during cardiac
remodelling (Yin et al. 2017).
As mentioned earlier, ET-1 is a potent vasoconstrictive
peptide secreted by ECs, acting on ECs and CMs,
which both express ET receptors. Evidence that it
may act as a paracrine regulator of cardiac hyper-
trophy first came from studies on cultured neonatal
rat ventricular CMs, which responded to ET-1 by
increasing protein synthesis and cell size, as well as by
reactivating the fetal gene programme (Ito et al. 1991). In
final stages of pressure overload-induced cardiac hyper-
trophy, ET-1 is upregulated and is likely responsible for
the enhanced vasoconstriction and compromised end-
othelial NO function, which induces oxidative stress and
eventually leads tobothCMloss andvasculardegeneration
(Tsai et al. 2017). Yet, the EC-specific deletion of ET-1
worsens the degree of hypertrophy and cardiac function
in the same animal model, indicating that either excessive
or insufficient ET-1 signalling is detrimental in this
context and that adequate levels of ET-1 are required
for a proper cardiac adaptation of the heart to the
increased pressure (Heiden et al. 2014). Furthermore,
ET-1 is up-regulated by ECs in response to Ang-II
through a mechanism involving the receptor-mediated
mobilization of intracellular calcium and activation of
protein kinase C (Emori et al. 1991). Finally, ECs increase
the production of ET-1 in response to mechanical stretch,
which invariably occurs during pressure overload (Hasdai
et al. 1997). Collectively, these data indicate that ECs sense
various signals associated to increased blood pressure,
i.e. Ang-II during renovascular hypertension, or more
generally mechanical stretch, and respond by releasing
ET-1,which is able to induceCMhypertrophy (vanWamel
et al. 2001). Despite these multiple indications of the
involvement of the ET-1 system in the pathogenesis of
cardiac dysfunction, results with ET receptor antagonists
in congestive heart failure have been disappointing. While
some earlier studies have suggested benefit (Luscher et al.
2002), larger studies have been neutral, with indication of
possible worsening of the patient’s conditions (O’Connor
et al. 2003), similar to what has been more recently
observed in patients with HFpEF and pulmonary hyper-
tension (Koller et al. 2017).
NRG-1 secreted by ECs also induces CM hypertrophic
growth, consistent with the observation that mice with
cardiac specific deletion of the ErbB2 receptor develop
dilated cardiomyopathy. Inhibition of the NRG-1/ErbB
signalling during pregnancy results in left ventricle
dilation and decreased cardiac output, associated with
decreased survival to pregnancy (Lemmens et al. 2011).
Thus, EC–CM crosstalk via NRG-1/ErbB signalling also
plays a crucial role during cardiac adaptation to stress.
During both pregnancy and pressure overload, levels
of PLGF are increased upon production by both CMs
and ECs. This induces capillary growth and fibroblast
proliferation, which secondarily supports cardiac hyper-
trophy through intermediate paracrine growth factors,
including IL-6 (Yao et al. 2005; Accornero et al. 2011).
Finally, a major player in the EC–CM crosstalk during
cardiac remodelling is Apelin (APLN), a secreted protein
binding to the G-protein coupled receptor APJ. In the
heart, APLN is mainly produced by endocardial cells and
ECs, while its APJ receptor is expressed by CMs, ECs
and smooth muscle cells (Kleinz et al. 2005). Consistent
with the broad expression of the receptor, the acute
administration of APLN reduces the vasomotor tone
with positive chronotropic and inotropic effect, as well
as a trend towards an increase in lusitropy (Ashley
et al. 2005). While initial biochemical studies suggested
a beneficial effect of APLN during cardiac remodelling
based on the ability of APJ to activate Gαi, thus activating
cardio-protective pathways (Rockman et al. 2002), genetic
models have recently revealed a more complex scenario.
While APJ knockout mice are partially protected from
pressure-overload cardiac hypertrophy and transition
to heart failure, APLN knockout mice develop a
normal hypertrophic response. This apparent discrepancy
suggests that the APJ receptor may be activated also by
APLN-independentmechanisms. In fact, the APJ receptor
can also act as a mechanosensor, able to transduce
pro-hypertrophic stimuli in a G-protein-independent,
but β-arrestin-dependent manner, upon cell membrane
stretch (Scimia et al. 2012). Recently, the generation of
both CM- and EC-specific APJ knockout animals has
revealed that its role as ligand-independent stretch sensor
controlling cardiac hypertrophy is essentially exerted on
CMs, with minimal, if not null, role of ECs in this process
(Parikh et al. 2018).
Endothelial cell–cardiomyocyte crosstalk during
ischaemia
Cardiac ischaemia is a clinical condition in which
the importance of CM-derived factors influencing the
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vasculature is crucial. Increasing evidence indicates that a
major, if not theonly,mechanismbywhich cell therapy can
be beneficial after myocardial infarction is by replenishing
cytokines and growth factors that can no longer be
produced by the deadCMs and that act on endothelial cells
inducing angiogenesis. At the same time, CMs also convey
anti-angiogenic signals to ECs. As mentioned before,
RBPJ in CMs antagonizes HIFs and inhibits the secretion
of pro-angiogenic molecules, thereby desensitizing the
angiogenic response to hypoxia (Diaz-Trelles et al. 2016).
Whether ischaemic ECs convey protective or toxic
signals (or both) to CMs is controversial. On the one
hand, multiple evidence supports the idea that ECs can
improve CM survival after ischaemia. The generation of
ROS, includingH2O2, in response to ischaemia, stimulates
the release ofNRG-1 fromECs and the activation of ErbB4
signalling in CMs, with their protection from apoptotic
cell death induced by ischaemia–reperfusion (Kuramochi
et al. 2004). Accordingly, NRG-1 heterozygous knockout
mice are hypersensitive to doxorubicin-induced cardio-
toxicity (Liu et al. 2005), which is known to be sustained by
the generation of ROS, similar to ischaemia–reperfusion
injury. On the other hand, under hypoxic conditions
cardiac ECs release transforming growth factor β, which
in turn promotes endothelial to mesenchymal transition
(EndoMT) inanautocrine loop,but also induces apoptosis
in CMs (Sniegon et al. 2017). While several studies have
reported that EndoMT contributes to the development of
cardiac fibrosis after ischaemia or in other pathological
settings (Xu et al. 2016), recent progresses in genetic
lineage tracing has challenged its role in vivo after cardiac
injury (Li et al. 2018), warranting further studies to
confirm the extent and function of EndoMT after cardiac
ischaemia.
Multiple secreted factors have been implicated in the
response to cardiac ischaemia, often exerting pleiotropic
functions, including maintenance and expansion of the
coronary vasculature, remodelling of the extracellular
matrix and protection of the CMs that have survived in
the peri-infarct region. One example is follistatin-like 1
(Fstl1), which is highly expressed by ischaemic CMs and
acts in an autocrine manner to promote myocyte survival
by binding to the disco-interacting protein 2 homolog A
(DIP2A) receptor.This receptorwas shown tobe expressed
and induce Akt activation in ECs (Ouchi et al. 2010).
However, its actual expression by cardiac ECs andwhether
it could mediate post-infarction coronary angiogenesis
still remain open questions.
Anadditional,well documented, cardioprotective factor
is Ang1. Besides its role in cardiac development, which
was mentioned before, Ang1 promotes CM survival
via integrin-β1-mediated ERK activation and preserves
cardiac functionupon ischaemia–reperfusion inmice (Lee
et al. 2011). At the same time, Ang1 also acts on cardiac
ECs by regulating VE-cadherin phosphorylation and
preventing vascular leakage in different models of cardiac
ischaemia (Takahashi et al. 2003).
Finally, PDGF is an important signal mediating
EC–CM crosstalk in ischaemic conditions. PDGF is
a dimeric glycoprotein that can be composed of two
A subunits (PDGF-AA), two B subunits (PDGF-BB),
or one of each (PDGF-AB). Primary cardiac micro-
vascular ECs constitutively express PDGF-A, but not
PDGF-B. Their co-culture with cardiac myocytes induces
the expression of PDGF-B, resulting in the secretion of
PDGF-AB. PDGF-AB in turn acts in an autocrine manner
to up-regulate the expression of von Willebrand factor,
VEGF and VEGFR-2, thus enhancing the haemostatic
and angiogenic properties of ECs (Edelberg et al. 1998).
While the mechanism by which ECs sense the presence
of CMs and start producing PDGF-B are completely
unknown, it is interesting to note that aged ECs lose
this response. Consistently, treatment of the heart with
PDGF-AB restored the angiogenic capacity of the aged
myocardium in a rat model of cardiac ischaemia, limiting
the extent of myocardial infarction (Edelberg et al. 2002).
PDGF-BB also activates Akt phosphorylation in CMs in
a time- and dose-dependent manner, thus preventing
apoptosis after myocardial infarction (Hsieh et al. 2006a).
As already introduced before, intercellular
communications can also occur via extracellular
vesicles, including exosomes. Over the last few years,
several studies have reported that exosomes modulate
angiogenesis in various organs, including the heart, and
that, in particular, exosomes produced by ischaemic
CMs can stimulate cardiac angiogenesis, at least in part
through the delivery of pro-angiogenic miRNAs (i.e.
miR-222 and miR-143) (Ribeiro-Rodrigues et al. 2017).
An overall view of the EC–CM crosstalk in the ischaemic
heart is provided in Fig. 5.
Endothelial cell–cardiomyocyte crosstalk in cardiac
regeneration
Different from the adult mammalian heart, which has a
very limited regenerative potential and heals any injury
through scarring, the heart of some lower vertebrates, such
as fish and amphibians, is able to regenerate new myo-
cardium after damage. In both zebrafish and axolotls the
regenerative process starts with the formation of a blood
clot, followed by CM cell cycle re-entry and proliferation
(Flink, 2002; Poss, 2007). Neonatal rodents can also
regenerate their heart, producing newCMs after either the
resection of the cardiac apex or the induction of a myo-
cardial infarction,while they lose this regenerative capacity
after the first week of life (Porrello et al. 2011; Sadek
et al. 2014). Furthermore, anecdotal evidence indicates
that the humanheartmight also possess some regenerative
potential during early post-natal life (Haubner et al. 2016).
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Several studies have shown that the epicardium, once
properly activated, can give rise to fibroblasts, smooth
muscle cells, endothelial cells and, to a lesser extent,
also cardiomyocytes, able to colonize the damaged myo-
cardium promoting cardiac repair. The role of the
epicardium in cardiac regeneration has been extensively
discussed elsewhere (Cao & Poss, 2018; Simo˜es & Riley,
2018) and does not fall into the focus of this review.
While the major focus in cardiac regeneration has been
on the formation of new CMs, it is obvious that the
regenerated area has to be properly vascularized. This
occurs through the proliferation and migration of ECs
residing in the vessels of the surrounding cardiac tissue
(Marin-Juez et al. 2016). Less obvious is the observation
that in both zebrafish and neonatal mice, ECs invade
the damaged area well before CMs start proliferating,
indicating that angiogenesis invariably precedes heart
Figure 5. Endothelial cell-cardiomyocyte crosstalk during
ischaemia
Secreted molecules mediate a bidirectional signalling between adult
endothelial cells (labelled by anti-CD31 antibodies in green) and
cardiomyocytes (labelled by anti-α-actinin antibodies in red) upon
ischaemia. Nuclei are stained in blue by DAPI. The dashed arrows
indicate the direction of the signals. Molecules secreted by
endothelial cells are indicated on the left, while those secreted by
both cell types are in the middle. Molecules acting in autocrine
manner are indicated by curved arrows. Ang1, angiopoietin-1; Fstl1,
follistatin-like 1; NRG-1, neuregulin-1; PDGF, platelet-derived growth
factor; TGF-β, transforming growth factor β.
regeneration (Marin-Juez et al. 2016). This also suggests
that the new vessels not only provide oxygen and nutrients
to proliferating CMs, but likely regulate the regenerative
process, similar to what occurs in the liver, in the lung and
in the pancreas (Ding et al. 2011, 2014; Kao et al. 2015).
The identification of the molecular mechanisms by
which ECs and CMs communicate in these models stands
as a crucial step toward the development of innovative and
effective strategies promoting cardiac regeneration.
In vitro models to study the crosstalk between
endothelial cells and cardiomyocytes
Most of the current knowledge on the molecular
mechanisms controlling heart development and disease
has been obtained using in vivo models. Yet, animal
models are expensive, have a low-throughput power and
do not allow one to dissect the intercellular crosstalk in
detail. In vitro models instead can be manipulated to
control different variables, are cheaper and suitable for
automation for big data analysis. Although the complex
architecture of the cardiac muscle and its mechanical
function are very difficult to reproduce ‘in a dish’, artificial
cardiac tissue has been produced over the years using a
variety of approaches, which have been very useful in
investigating the EC–CM crosstalk.
Adult CMs isolated from the murine heart maintain
a structured sarcomeric organization, mature electrical
properties and beat. Unfortunately, these cells are difficult
to isolate and maintain in culture, rapidly lose their
mature phenotype in the presence of serum and do not
easily integrate into three-dimensional in vitro models.
Neonatal murine ventricular CMs, together with CMs
derived from either induced pluripotent stem cells (iPSC)
or human embryonic stem cells (hESC) are the most
common sources of myocytes for in vitro studies, due
to the possibility of obtaining large numbers of cells
and also of introducing genetic modifications to mimic
pathological conditions. Yet, these cells have an immature
phenotype, characterized by small size, immature cyto-
skeletal and sarcomeric organization and abnormal
electrical properties.
ECs are easier to isolate, but their organ source and the
age of donor are highly variable in the various models
used so far. Several studies have relied on the use of
cells derived from extra-cardiac tissues, such as HUVECs
or murine ECs derived from the aorta. Alternatively,
commonly employed ECs are human or murine cardiac
microvasculature ECs, human coronary ECs, iPSC- and
hESC-derived ECs.
The EC–CM in vitro crosstalk has been analysed using
either classical co-culture systems or more sophisticated
three-dimensional engineered tissues. The easiest set-up is
the two-dimensional co-culture ofCMsandECs.This is an
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easy and inexpensive approach, only requiring a medium
that allows preservation of both cell types and is the only
platform suitable to study the crosstalk between adult CMs
and other cells. More specifically, the existence of soluble
signals acting in a paracrine manner between ECs and
CMs has been defined using transwell systems, using both
neonatal (Zhang et al. 2015) and adult (Chiu et al. 2016)
cardiac cells.
Since two-dimensional cultures fail to recapitulate
many features of the native tissue, including multiple
cell–cell interaction, cell shape and the stiffness of
the substrate used for cell adhesion (Baker & Chen,
2012), multiple approaches of three-dimensional tissue
engineering have been developed in an attempt to create
functional cardiac tissues or organoids.
Different scaffolds have been considered, composed of
a variety of bio-materials, including chitosan (Hussain
et al. 2013), hydrogels (Narmoneva et al. 2004) and porous
sponges of poly-L-lactic andpolylactic-glycolic acid (Caspi
et al. 2007), on which CMs and ECs can be seeded or
encapsulated at different ratios. Alternatively, CMs can be
seeded on a pre-formed vascular network (Narmoneva
et al. 2004). Two- and three-dimensional miniaturized
chips have also been developed for cell micro-patterning
and anisotropic cultures to achieve controlled cell–cell
interaction and proper myofibril orientation. However,
these systems are still poorly exploited for the study of
EC–CM crosstalk (Kofron & Mende, 2017). A promising
approach stems fromthecell sheet engineering technology,
which allows generation of dense and multi-stratified
tissue patches suitable for both drug screening and tissue
transplant studies. ECs co-cultured in CM sheets are
able to spontaneously create a microvasculature network
within the cardiac tissue and to connectwith the capillaries
of the host myocardium upon transplantation (Sekine
et al. 2008; Stevens et al. 2009).
Beside scaffold-based cultures or controlled cell
layering, many three-dimensional systems exploit the
capacity of cells to self-aggregate forming cardiac
organoids. For instance, embryoid bodies seeded on an
EC feeder layer show enhanced differentiation towards
the CM phenotype, with faster and synchronized beating
(Pasquier et al. 2017). Stem cell-derived CMs self-organize
into a spherical cardiac microtissue when cultured in
either hanging drops or spherical-bottom low adhesion
plates (Fennema et al. 2013). These CM organoids display
enhanced contractility and functional maturation when
primary coronary ECs are incorporated into the micro-
tissue. Interestingly, the same effect is not achieved if
ECs have extra-cardiac origin, suggesting that organotypic
signals are required to promote hESC-derived CM
maturation (Ravenscroft et al. 2016). Instead of mixing
the two cell types, hESCs could be induced to differentiate
toward a cardiac mesodermal fate, in order to generate
simultaneouslybothECsandCMs(Giacomelli et al.2017).
Overall, thesemodels support amajor role for cardiac ECs
in promoting CM structural and functional maturation.
To further reproduce cardiac microenvironment cues,
several studies have introduced cyclic stretch or electrical
stimuli on both two- and three-dimensional co-culture
systems to mimic the rhythmic beating of the heart.
Mechanical stretch induces several changes in in vitro
cardiac tissues, such as hypertrophy, metabolic shift,
increased contractility and stem cell differentiation
(Tulloch et al. 2011). However, a standardized method
for cyclic stretch conditioning of engineered cardiac tissue
has not been achieved yet, due to the variability of
technological devices used to apply mechanical stretch
and the heterogeneity of culture systems.
Despite the recent optimization of media and
biomaterials used to recreate the complex cardiac
three-dimensional architecture in a dish, the models
currently available are very heterogeneous, difficult to
compare and do not provide a standard for the effective
identification and validation of the mechanisms and
molecules involved in the EC–CM crosstalk.
Conclusions
While revising and discussing the mechanisms by which
ECs and CMs communicate during heart development
and disease, it emerged that a substantial amount of
information is available on the signals generated by
ECs and able to influence CM structure and function.
Yet, the way CMs can modulate EC biology in the
heart still remains poorly investigated. While it is
known that pro-hypertrophic stimuli increase myocardial
vascularization through the secretionof angiogenic factors
by CMs, the exact mechanisms coordinating the workload
with the sprouting of new vessels in the heart still remain
elusive. The generation of CM-specific knockout animals
has provided conflicting results, indicating that these
cells are able to send both stimulatory and inhibitory
signals to ECs and that these signals are probably
integrated within a complex scenario. Multiple cell types,
hormones, metabolites and growth factors contribute
to the regulation of survival, function and regeneration
of cardiac vessels in both normal and pathological
conditions. This complexity could explain, at least in
part, the reasons why most of the clinical trials aimed at
inducing therapeutic angiogenesis in the heart have failed
so far, since in all cases these trials have been based on the
delivery of a single factor (van der Laan et al. 2009; Mitsos
et al. 2012).
In addition, scanty information is available on the
relevance of the EC–CM crosstalk during a series of
pathological conditions that often affect the heart,
including the onset and perpetuation of arrhythmias,
genetic cardiomyopathies, valve disease and cardiac
transplantation.
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Most of our current knowledge concerns the role of
proteins secreted by either ECs or CMs and capable of
acting on either or both cell types in a paracrine or auto-
crine fashion. However, it is becoming clear that ECs and
CMs can communicate through alternative mechanisms,
including the establishment of gap junctions and direct
cell-to-cell contact, as well as the secretion of vesicles. In
addition, ECs act asmechanosensors, couplingmyocardial
contraction to haemodynamic changes. For instance,
TRPC channels, which are diffusely present in both atrial
and ventricular CMs (Seo et al. 2014), are also expressed
by endocardial ECs and increase the amplitude of calcium
transients in normal CMs. Notably, this positive inotropic
effect is lost in response to acute stretch. Whether these
types of inter-cellular connections play amajor role during
normal heart development and/or disease progression still
remains largely unexplored.
Furthermore, for many molecules able to impact on
either EC or CM function, the exact cellular source
and the stimuli leading to their production are not yet
defined. While this review specifically focuses on the
direct crosstalk between ECs and CMs, many of these
paracrine signals also exert pleiotropic actions on other
cell types residing in the heart, such as fibroblasts, end-
ocardial and pericardial cells, resident macrophages, and
circulating immune cells. At the same time, other cells
in the heart, as well as other organs, produce the same
molecules, and their levels are importantly modified by
several physiological and pathological conditions. For
instance, ageing is known to be associated with both
EC and CM dysfunction, resulting in heart hypertrophy
and stiffness. During ageing, expression of both APLN
and its APJ receptor are decreased and APLN infusion
in 15-month-old mice reduces cardiac hypertrophy (Rai
et al. 2017). On the other hand, ET-1 increases in aged
hearts, although its pathogenic role in determining cardiac
stiffness seems to be related to its effect on cardiac
fibroblasts rather than CMs (Wang et al. 2015). Additional
complexity stems from the fact the heart is at the centre
of a complex organism, in which multiple tissues actively
produce large amounts of soluble molecules that flows
through the cardiac pump and thus can further modulate
cardiac EC and CM function, possibly influencing their
crosstalk. For example, the thyroid hormones L-thyroxine
(T4) and 3,5,3′-triiodo-L-thyronine (T3) are well known
inducers of CM hypertrophy and, at the same time,
exert a pro-angiogenic function through direct binding to
integrin αvβ3 on the EC surface, also modulating VEGF
and FGF signalling (Luidens et al. 2010). Furthermore,
LPL activity on the EC luminal surface is modulated
by angiopoietin-like proteins that can be produced by
the heart but also by the liver (Kersten, 2014). Finally,
both Ang-II and ET-1 are produced through a complex
multi-organ cascade, relyingonangiotensinogen secretion
by the liver, its conversion to Ang-I by renin produced by
the kidney and finally conversion of Ang-I into Ang-II
by angiotensin converting enzyme, mainly produced by
lung ECs (Boehm & Nabel, 2002). Further investigation
is required to understand to what extent these signals are
interconnected and whether they result in either synergic
or antagonistic effects.
The establishment of more complex in vitro models,
integrating multiple cell types in a three-dimensional
structure, and their miniaturization to render them
suitable to screening approaches, rather than investigating
the effect of a single molecule on a single cell type, will
likely help shed light on several of these outstanding
questions.
Finally, how this information could be exploited to
interfere with the onset and pathogenesis of cardiac
disease is a matter of active research, which might lead
to innovative therapeutic approaches in the near future.
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